Reprise Biomedical is focused on the development and commercialization of biological medical devices that offer advanced solutions for wound healing. In 2019, Reprise took ownership of two products, under a proprietary perfusion decellularization technology license from the University of Minnesota, MiroDerm biologic wound matrix for advanced wound management and MiroFlex biologic matrix for soft tissue reinforcement. Reprise is committed to delivering novel solutions which address unmet surgical needs for advanced wound care. Our transformational, Miro3D wound matrix, is an example of that commitment. Miro3D broadens our wound management portfolio by offering a unique three-dimensional solution for deep and tunnelling wounds.